| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 365 | 456 | 478 | 517 |
| Cost of Material Consumed | 232 | 326 | 329 | 200 |
| Change in Inventory | 4 | -17 | 3 | 13 |
| Gross Margins | 36.44 | 28.51 | 31.17 | 61.32 |
| Employee Benefit Expenses | 33 | 38 | 39 | 40.8 |
| Other Expenses | 65 | 64 | 79 | 80 |
| EBITDA | 31 | 45 | 28 | 183.2 |
| OPM | 8.49 | 9.87 | 5.86 | 35.44 |
| Other Income | 4 | 4 | 5 | 6 |
| Finance Cost | 7 | 7 | 8 | 5 |
| D&A | 9 | 9 | 8 | 10 |
| EBIT | 22 | 36 | 20 | 173.2 |
| EBIT Margins | 6.03 | 7.89 | 4.18 | 33.5 |
| PBT | 19 | 32 | 17 | 29 |
| PBT Margins | 5.21 | 7.02 | 3.56 | 5.61 |
| Tax | 3 | 5 | 6 | 7.4 |
| PAT | 16 | 27 | 11 | 21.6 |
| NPM | 4.38 | 5.92 | 2.3 | 4.18 |
| EPS | 23.19 | 39.13 | 15.94 | 31.3 |
Financial Ratios |
2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 8.49 | 9.87 | 5.86 | 35.44 |
| Net Profit Margin | 4.38 | 5.92 | 2.3 | 4.18 |
| Earning Per Share (Diluted) | 23.19 | 39.13 | 15.94 | 31.3 |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | 41 | 45 | 59 | 53 |
| CWIP | 0 | 10 | 1 | 3 |
| Investments | 0 | 0 | 0 | 0 |
| Trade Receivables | 105 | 103 | 101 | 87 |
| Inventory | 69 | 86 | 80 | 75 |
| Other Assets | 44 | 51 | 37 | 52.9 |
| Total Assets | 259 | 295 | 278 | 270.9 |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 6.9 | 6.9 | 6.9 | 6.9 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 41 | 67 | 77 | 101 |
| Borrowings | 98 | 93 | 68 | 35 |
| Trade Payables | 86 | 92 | 95 | 97 |
| Other Liabilities | 27.1 | 36.1 | 31.1 | 31 |
| Total Liabilities | 259 | 295 | 278 | 270.9 |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | 18 | 32 | 17 | 29 |
| OPBWC | 33 | 49 | 35 | 43 |
| Change in Receivables | -31 | 2 | -2 | 13 |
| Change in Inventories | -3 | -17 | 6 | 5 |
| Change in Payables | -12 | 1 | 0 | 6.2 |
| Other Changes | 16 | -1.1 | 17 | -13.9 |
| Working Capital Change | -30 | -15.1 | 21 | 10.3 |
| Cash Generated From Operations | 3 | 33.9 | 56 | 53.3 |
| Tax | 3 | -6 | -9 | -7.3 |
| Cash Flow From Operations | 6 | 27.9 | 47 | 46 |
| Purchase of PPE | -2 | -18 | -15 | -9 |
| Sale of PPE | 0 | 0 | 0 | 0 |
| Cash Flow From Investment | 0 | -18 | -15 | -8.6 |
| Borrowing | 0 | -5 | -29 | -31.7 |
| Dividend | 0 | 0 | 0 | 0 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | -9.6 | -9 | -8 | -5.6 |
| Cash Flow from Financing | -9.6 | -14 | -37 | -37.3 |
| Net Cash Generated | -3.6 | -4.1 | -5 | 0.1 |
| Cash at the Start | 12 | 8.6 | 4 | 0.3 |
| Cash at the End | 8.4 | 4.5 | -1 | 0.4 |
| Name | Designation | Experience | Linkedin Profile |
|---|---|---|---|
| Subhasis Chatterjee | MD | 25 yrs |
|
| Ravichandran Purushothaman | Director | 33 yrs |
|
| Prajakta Sangoram | Director, CA, CS | 13 yrs |
|
| Binu Antony Kuttickatt | Director | 20 yrs |
|